| Autor: |
Dopazo C; Department of HPB Surgery and Transplants, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain., Charco R; Department of HPB Surgery and Transplants, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain., Caralt M; Department of HPB Surgery and Transplants, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain., Pando E; Department of HPB Surgery and Transplants, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain., Lázaro JL; Department of HPB Surgery and Transplants, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain., Gómez-Gavara C; Department of HPB Surgery and Transplants, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain., Castells L; Hepatology Unit, Department of Internal Medicine, Hospital Vall d'Hebron, CIBERehd, Universidad Autónoma de Barcelona, Barcelona, Spain., Bilbao I; Department of HPB Surgery and Transplants, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain. |
| Abstrakt: |
We aimed to evaluate the safety and efficacy of low doses of anti-T-lymphocyte globulin (ATG)-based immunosuppression in preserving renal function and preventing liver rejection in liver transplant (LT) recipients with pretransplant renal dysfunction. We designed a prospective single-center cohort study analyzing patients with pre-LT renal dysfunction defined as eGFR<60 mL/min/1.73m 2 , who underwent induction therapy with ATG ( ATG group, n=20) . This group was compared with a similar retrospective cohort treated with basiliximab ( BAS group, n=20 ). An economic analysis between both induction therapies was also undertaken. In the ATG group, 45% and 50% of patients had recovered their renal function without acute cellular rejection (ACR) episodes at day 7 and 1 month after LT, respectively, versus 40% and 55% of patients in the BAS group (p=1). Renal function improved in both groups over time and no differences between groups were observed regarding one-year eGRF and one-year probability of ACR. Cost per patient of the ATG course was 403€ (r: 126-756) versus 2,524€ of the basiliximab course (p=0.001). In conclusion, induction with low dose of ATG or basiliximab in patients with pretransplant renal dysfunction is a good strategy for preserving posttransplant renal function; however the use of low-dose ATG resulted in a substantial reduction in drug costs. This trail is registered with ClinicalTrials.gov number: NCT01453218. |
Plný text